ACR/ARHP Annual Meeting 2013
Denosumab Increases Bone Mineral Density, Suppresses RA Progression
Significant increases in bone mineral density (BMD) were observed after 12 months of treatment with denosumab vs. placebo in patients with rheumatoid arthritis (RA) regardless of glucocorticoid use, according to a study presented at the 2013 ACR/ARHP Annual Meeting.
